NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Neuroplast

Neuroplast

Private
MaastrichtHealthcare & Life Scienceshttps://www.neuroplast.com/

Last Round

Series B

Nov 17, 2021

Total Funding Raised

$15.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neuroplast is a biotechnology company that develops the autologous stem cell platform product Neuro-Cells®, a treatment to combat neurodegeneration resulting from trauma, disease and ageing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

autologous stem cell therapyregenerative medicinespinal cord injurystem cell researchcell therapybiotechnologyneurodegenerative diseaseclinical trialsbone marrow-derived cellstissue repairpersonalized medicinebiologicsGMP manufacturingATMPadvanced therapy medicinal products

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neuroplast Comparables

Compare Neuroplast with similar companies based on industry and business-model similarity.

Neuroplast comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Matricelf Ltd
77%
Brainstorm Cell Therapeutics Inc.
77%
ReNetX Bio
74%

Neuroplast Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 17, 2021
Series AFeb 19, 2020

Neuroplast Investors

Notable investors and investment history

Neuroplast investors
InvestorRounds
819 Capital PartnersSeries A
Brightlands Venture PartnersSeries B, Series A
Lumana InvestSeries B
LIOFSeries B, Series A
Netherlands Enterprise AgencySeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2026

    Grew 43% QoQ from 7 to 10 employees.

Neuroplast Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neuroplast Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neuroplast's valuation, stock price, and market status.

Firmographic Details

HeadquartersMaastricht
Employee Range10
Year Founded2014
Last FundingNov 17, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.